Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by Benedict16thon Dec 21, 2020 12:39pm
124 Views
Post# 32153240

RE:RE:RE:RE:RE:RE:RE:I sense displeasure ...

RE:RE:RE:RE:RE:RE:RE:I sense displeasure ...Wag, since you are so smart, and I am not, how much $$$ did GBT earned/profits in the last quarter. In the last Year 
how many new drug licences has GBT and GUD got?
Unless GUD and GBT get scores/dozens of new small drugs and or large moving needle blockbuster new drug licence these two ponies are not going anywhere. The market so far has written GBT off. At this pace of drug licencing forget grandkids investing and think more five generation.  Where are the new drug deals and why they are not getting them is the real question. So we can conclude that either MNGT is not comptent to get new deals or there are no new deals to get and thus GUD MNGT business plan is deeply flawed 
<< Previous
Bullboard Posts
Next >>